Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Radiotherapy & Radiosurgery
Cyberknife for prostate cancer
What CyberKnife stereotactic body radiation therapy (SBRT) is for localised prostate cancer, how robotic real-time tracking delivers high radiation doses in 4 to 5 sessions, clinical evidence and PSA control, approximate costs in Turkey compared with the UK and US, recovery expectations, urinary and bowel risks, and how to verify qualified radiation oncology centres.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Radiotherapy & Radiosurgery
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Cyberknife for Prostate Cancer
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is CyberKnife for prostate cancer and how does it work?
Cyberknife for prostate cancer is a non-invasive radiation treatment delivering stereotactic body radiation therapy (SBRT) to malignant prostate tissue with sub-millimetre precision. Rather than undergoing surgical removal of the prostate gland or attending hospital daily for seven to nine weeks of standard external beam radiotherapy, patients receive targeted ablative radiation across four to five outpatient sessions. The system mounts a lightweight linear accelerator on a multi-jointed robotic arm, guided by continuous image-tracking cameras that monitor internal organ movement during beam delivery.
Because the prostate gland sits immediately adjacent to the rectum, bladder, and urethra, natural internal movements can displace the gland during treatment. CyberKnife detects this movement and adjusts the radiation beams automatically. This targeted approach is primarily used for organ-confined, low-risk and intermediate-risk prostate tumours. This guide explains how the robotic technology works, what clinical trials report, approximate costs in Turkey compared with the UK, US, and Germany, recovery milestones, and how to evaluate accredited radiation oncology departments. For other cancer care pathways, see our guide to oncology treatments in Turkey.
How robotic real-time tracking delivers prostate SBRT
The prostate shifts continuously inside the pelvis as the bladder fills with urine and gas passes through the rectum. In conventional radiotherapy, wide safety margins are added around the prostate to ensure the moving target receives the prescribed dose, which inadvertently exposes healthy bowel and bladder tissues to radiation. CyberKnife replaces wide safety margins with active robotic tracking.
Prior to treatment, a specialist implants three or four tiny gold fiducial markers into the prostate under local anaesthesia. During each treatment fraction, ceiling-mounted X-ray cameras capture continuous stereoscopic images of these markers. The tracking software detects any motion across six dimensions—translation and rotation—and directs the robotic arm to reposition the beam instantly. Unlike gamma knife systems built strictly for stationary cranial lesions, CyberKnife tracks moving extracranial anatomy, reducing treatment margins to 1–2 millimetres and sparing sensitive rectal and urinary nerves.
Does CyberKnife for prostate cancer work? Evidence and PSA outcomes
Clinical trials confirm that does cyberknife for prostate cancer work reliably for localised tumours. Multi-centre trials, such as the prospective PACE-B study published in peer-reviewed medical oncology journals, evaluated prostate SBRT directly against conventional and moderately fractionated radiotherapy. Five-year findings demonstrated biochemical recurrence-free survival rates exceeding 95% for low-risk and intermediate-risk prostate cancer, matching tumour-control rates achieved with radical prostatectomy surgery and prolonged 39-session radiotherapy courses.
Major professional organisations, including the American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO), endorse SBRT as a standard treatment option for organ-confined disease. The concentrated doses exploit the unique radiation sensitivity of prostate cancer cells. However, CyberKnife cannot cure widespread metastatic disease spread across distant bones, and it does not reduce PSA levels overnight; prostate-specific antigen declines gradually over 18 to 36 months toward a low nadir.
CyberKnife for prostate cancer cost in Turkey compared with the UK, US and Germany
The figures below provide approximate complete treatment cost ranges for stereotactic prostate radiosurgery. These are indicative ranges rather than individual hospital quotes, as a personalised cyberknife for prostate cancer price depends on staging requirements, preparatory procedures, and package inclusions.
| Country | Approximate cost range |
|---|---|
| Turkey | €4,500 – €9,000 |
| United Kingdom | €11,000 – €22,000 |
| United States | €20,000 – €45,000 |
| Germany | €12,000 – €24,000 |
Several clinical elements influence cyberknife for prostate cancer cost. Key factors include pre-treatment multi-parametric MRI and simulation CT scans, fiducial marker insertion, whether a protective hydrogel rectal spacer is placed, medical physics planning fees, and hospital stay or hotel accommodation. In Turkey, packages frequently cover the complete radiosurgery fractions, physics planning, consultations, transfers, and language assistance. You can request a personalised estimate via our free quote service.
CyberKnife SBRT, conventional IMRT or radical prostatectomy?
Patients facing localised prostate cancer generally weigh CyberKnife against standard intensity-modulated radiation therapy (IMRT) and radical prostatectomy surgery. Some clinics also utilise tomotherapy for continuous helical delivery.
| Treatment option | Best suited to | Typical limits |
|---|---|---|
| CyberKnife SBRT | Organ-confined, low to intermediate-risk prostate cancer wanting non-surgical outpatient treatment in 4–5 sessions | Not suitable for widespread metastases or very large prostate glands causing severe urinary obstruction |
| Conventional IMRT / VMAT | Broad risk categories, including cases needing extensive elective pelvic lymph node irradiation | Requires daily hospital visits over 4 to 8 weeks (20 to 40 sessions), increasing overall travel time |
| Radical Prostatectomy | Healthy patients preferring complete surgical organ removal with definitive surgical pathology staging | Invasive surgery requiring hospital admission, general anaesthesia, catheter use, and longer physical recovery |
Radical prostatectomy removes the entire gland, offering definitive surgical pathology and an immediate drop in PSA, but requires general anaesthesia, hospitalisation, and a temporary urinary catheter. Conventional IMRT provides excellent tumour control but demands 20 to 40 hospital visits over several weeks. CyberKnife condenses the curative radiation into four or five outpatient sessions without surgery or extended travel.
Who is a suitable candidate for prostate CyberKnife treatment?
Suitability for cyberknife for prostate cancer in Turkey is assessed by a multidisciplinary oncology board based on established clinical criteria:
- Histologically confirmed adenocarcinoma confined to the prostate gland (clinical stages T1c to T2c).
- Low-risk or favourable-to-unfavourable intermediate-risk disease (Gleason score 6 or 7, Grade Group 1–3).
- Baseline PSA level generally below 15 to 20 ng/mL.
- Mild to moderate baseline urinary symptoms (International Prostate Symptom Score below 15).
- Men seeking an outpatient non-surgical approach or those who carry high anaesthetic risks.
CyberKnife is not suitable if the cancer has spread to distant lymph nodes or bones. Severe baseline urinary obstruction increases the risk of acute urinary retention after radiation swelling. A very large prostate gland (over 80–100 cc) may require preliminary hormone therapy to shrink the gland before treatment. Other contraindications include active inflammatory bowel disease and prior pelvic radiation.
The CyberKnife treatment process: fiducial markers to final fraction
The treatment follows a carefully orchestrated outpatient pathway:
- Fiducial marker placement: About a week before radiation, three or four tiny gold seeds are inserted into the prostate under local anaesthesia using ultrasound guidance. A biodegradable hydrogel rectal spacer may also be injected to push the rectal wall safely away from the prostate.
- Imaging and simulation: You attend the hospital for a high-resolution simulation CT scan and pelvic MRI. A custom vacuum cushion is molded around your legs to ensure a stable, reproducible position.
- Treatment planning: Medical physicists and radiation oncologists map the target volume and organs at risk. Specialised software calculates thousands of beam trajectories to concentrate radiation on the tumour while sparing healthy tissue.
- Delivery sessions: Over one to two weeks, you receive four or five sessions on alternate days. Each fraction lasts 30 to 45 minutes. You lie clothed on a cushioned table while the robotic arm moves quietly around you. The session causes no physical pain, requiring no incisions or urinary catheters.
CyberKnife for prostate cancer recovery and short-term side effects
Because stereotactic radiosurgery involves no incisions, cyberknife for prostate cancer recovery is rapid compared to surgery. Most international patients stay in Turkey for 10 to 14 days, which covers marker placement, simulation scans, computer dosimetry planning, and five alternate-day treatment sessions.
Mild acute side effects can arise toward the end of treatment as tissues react to radiation:
- Urinary changes: Increased frequency, urgency, or mild burning when urinating usually peak one to two weeks post-treatment and resolve within four to eight weeks. Doctors often prescribe temporary alpha-blocker medication (such as tamsulosin) to ease flow.
- Bowel changes: Mild rectal urgency or looser stools may occur, but symptoms are typically minor and temporary, particularly when a hydrogel spacer is used.
- Fatigue: Mild tiredness can develop during the second week as the body clears cellular debris. Daily walking and hydration help maintain energy.
Patients resume desk work and normal daily routines immediately. Strenuous bicycling or heavy lifting should be avoided for three to four weeks. A final check with the radiation oncologist ensures you are fit to fly home.
Potential risks and long-term urinary, bowel and sexual complications
While robotic precision significantly limits radiation exposure to adjacent anatomy, therapeutic radiation carries recognised risks documented by organisations such as the NHS, ASTRO, and ESTRO:
- Urinary risks: Radiation cystitis (bladder irritation) occurs in about 1% to 3% of patients. Urethral stricture (scar narrowing of the urethra) affects fewer than 2% to 3% and can be treated if necessary. Complete urinary incontinence is rare, affecting under 1% to 2% of patients.
- Bowel risks: Radiation proctitis causing minor rectal bleeding or discomfort occurs in approximately 1% to 3% of cases. Placing a temporary hydrogel spacer significantly lowers this risk by maintaining physical separation between the prostate and rectum.
- Sexual function: Unlike surgical nerve damage which is immediate, radiation-related erectile changes emerge gradually over two to five years as microscopic vessels slowly change. Around 60% to 80% of previously potent men maintain satisfactory erectile function post-SBRT, often supported by medication if needed.
A qualified radiation oncology team will discuss your baseline health and apply stringent dose constraints to preserve your long-term quality of life.
Realistic outcomes: what PSA monitoring and imaging show over time
Understanding post-treatment monitoring prevents undue concern after cyberknife for prostate cancer. Unlike surgery where the prostate is excised and PSA immediately drops to undetectable levels, radiation causes gradual tumour cell death while preserving benign prostate tissue.
Consequently, PSA levels fall slowly over 18 to 36 months before reaching their lowest point, termed the PSA nadir. A nadir below 0.5 ng/mL generally indicates excellent local control. Between 12 and 24 months after treatment, up to 30% of men experience a "PSA bounce"—a temporary, self-limiting rise of 0.2 to 1.0 ng/mL followed by an automatic drop. This bounce represents a benign inflammatory reaction within irradiated prostate tissue rather than tumour recurrence. Routine monitoring involves a serum PSA blood test every three to six months for the first two years, then annually.
Choosing a radiation oncology centre in Turkey and key questions to ask
When researching cyberknife for prostate cancer Turkey, select an internationally accredited hospital with dedicated linear accelerator bunkers and on-site medical physicists. Read our how it works overview for planning details, and submit your records through our free quote form for an initial case review.
Avoid centres that make absolute cure claims, pressure you to book before evaluating your imaging, or lack multi-disciplinary tumour boards. Before confirming treatment, ask the clinical team:
- Will a multidisciplinary tumour board review my biopsy slides and MRI scans?
- What CyberKnife system do you use, and how many prostate SBRT cases does your team treat annually?
- Do you routinely use fiducial markers and a hydrogel rectal spacer?
- How do your medical physicists verify each radiation plan before delivery?
- What support is available if I experience acute urinary symptoms while in Turkey?
- How will you coordinate follow-up PSA records with my doctor at home?
Hospitals with Oncology in Turkey
Frequently asked questions
CyberKnife for prostate cancer is a non-invasive robotic stereotactic body radiation therapy (SBRT) system that delivers high-dose radiation to the prostate with sub-millimetre precision. It uses real-time motion tracking to adjust for natural internal movements, treating organ-confined prostate tumours in four to five outpatient sessions without surgery, incisions, or hospital stays.
Yes, clinical trials including the multi-centre PACE-B study demonstrate that SBRT delivers five-year tumour control and biochemical recurrence-free survival exceeding 95% for low-risk and intermediate-risk localised prostate cancer. These results match long-term outcomes achieved by radical prostatectomy and conventional two-month radiation courses, while requiring substantially fewer hospital visits.
CyberKnife treatment for prostate cancer in Turkey typically ranges from €4,500 to €9,000, compared with €11,000 to €22,000 in the UK and €20,000 to €45,000 in the US. Comprehensive packages usually include pre-treatment imaging, fiducial marker placement, medical physics planning, all radiation sessions, medical translation, and airport transfers.
Unlike cosmetic surgery, prostate cancer outcomes are evaluated biochemically rather than through visual photographs. Following CyberKnife, prostate-specific antigen (PSA) levels decline steadily over 18 to 36 months toward a low nadir, usually below 0.5 ng/mL. Successful treatment preserves surrounding tissue structure while effectively eradicating active malignant tumour cells within the gland.
Recovery is rapid because there are no surgical wounds. Most men resume light daily activities immediately after each session. Mild urinary urgency, frequency, or fatigue can occur during the first two to four weeks, gradually resolving within two months. Desk work can continue uninterrupted, while vigorous cycling should wait three to four weeks.
Radiation delivery causes no physical sensation; you simply lie still on a cushioned table while the robotic arm moves around you. Inserting fiducial markers beforehand involves brief local anaesthetic discomfort similar to a prostate biopsy. Afterwards, temporary urinary irritation or mild burning can occur, which is managed effectively with standard medications.
Long-term clinical registries tracking patients for ten years and beyond show durable cancer control comparable to radical surgery for localised tumours. The concentrated radiation permanently damages cancer cell DNA, preventing malignant replication. Long-term monitoring requires routine serum PSA blood tests every six to twelve months to confirm continued disease stability.
Primary risks include temporary urinary urgency, burning, or frequency, affecting patients during the first few weeks. Long-term complications documented by oncology registries include urethral stricture in under 3%, radiation cystitis or proctitis in 1% to 3%, and gradual erectile changes over several years. Permanent urinary incontinence is very rare, occurring in under 2%.
Neither option suits every patient. CyberKnife avoids surgical incisions, general anaesthesia, prolonged catheterisation, and high rates of stress incontinence, making it attractive for active men or those with surgical risks. Radical prostatectomy offers complete tissue removal and immediate pathology staging, but requires longer physical recovery and hospital admission.
Patients typically stay in Turkey for 10 to 14 days. This window accommodates initial consultation, fiducial marker placement, CT and MRI simulation scans, two to three days of precision computer dosimetry planning, and five treatment sessions delivered on alternate days, followed by a final clearance consultation before flying home.
Patient stories